Securities Code: 300246
Bond Code: 123065
Securities Abbreviation: Baolight
Bond Abbreviation: Baolight Convertible Bond
Announcement No.: 2026-052
Guangdong Baolight Medical Technology Co., Ltd.
Announcement on the Completion of Investment Projects, Termination of Partial Investment Projects, and Use of Remaining Raised Funds for Permanent Working Capital
The Company and all members of the Board of Directors guarantee the content of this information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Guangdong Baolight Medical Technology Co., Ltd. (hereinafter referred to as the "Company") held the 13th meeting of the 9th Board of Directors on August 4, 2026. The meeting deliberated and passed the "Proposal on the Completion of Investment Projects, Termination of Partial Investment Projects, and Use of Remaining Raised Funds for Permanent Working Capital." The Board of Directors agreed to terminate some projects and complete others within the investment projects, and to permanently supplement working capital with the remaining raised funds of RMB 60.6631 million (subject to the actual balance of the special account for raised funds at the time of transfer). This matter still needs to be submitted for deliberation and approval by the Company's shareholders' meeting before it can be implemented. The specific situation is hereby announced as follows:
I. Basic情况 of Raised Funds
- Basic情况 of Raised Funds
According to the "Approval on Guangdong Baolight Medical Technology Co., Ltd.'s Application for Issuing Shares to Specific Objects" (Zhengjian Permit [2021] No. 3736) issued by the China Securities Regulatory Commission on November 25, 2021, and with the approval of the Shenzhen Stock Exchange, the Company issued 28,723,404 shares of RMB common stock (A shares) at an issuance price of RMB 18.80 per share. The total amount of raised funds was RMB 539,999,995.20. After deducting issuance expenses of RMB 11,950,681.67 (excluding tax), the net amount of raised funds was RMB 528,049,313.53. The receipt of these raised funds was audited by Dahua Certified Public Accountants (Special General Partnership), who issued an audit report No. Dahua Yan Zi [2022] No. 000055.
- Previous Adjustments
(1) The 28th meeting of the 7th Board of Directors held on October 27, 2022, and the 2022 First Extraordinary General Meeting of Shareholders held on November 14, 2022, deliberated and passed the "Proposal on Adjusting the Investment Amount, Internal Investment Structure, Location, and Implementing Entity of Some Raised Fund Investment Projects." It was agreed that the Company would make appropriate adjustments to the investment amount, internal investment structure, location, and implementing entity of the "Baolight Blood Purification Industrial Base and R&D Center Project" while the total amount of raised funds remained unchanged. For details, please refer to the "Announcement on Adjusting the Investment Amount, Internal Investment Structure, Location, and Implementing Entity of Some Raised Fund Investment Projects" (Announcement No.: 2022-073) disclosed by the Company on the Juchao Information Network.